{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:36:39Z","timestamp":1740137799390,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T00:00:00Z","timestamp":1469577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Fight for Sight Denmark","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Bagenkop Nielsen Myopia Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Research Foundation of Region Zealand","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11695-016-2303-0","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T06:38:50Z","timestamp":1469601530000},"page":"408-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The IGF-Axis and Diabetic Retinopathy Before and After Gastric Bypass Surgery"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5250-4257","authenticated-orcid":false,"given":"Troels","family":"Brynskov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline Schmidt","family":"Laugesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Karen","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Frystyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben Lykke","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,27]]},"reference":[{"key":"2303_CR1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","volume":"116","author":"The Diabetes Control and Complications Trial Research Group","year":"1998","unstructured":"The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol. 1998;116:874\u201386.","journal-title":"Arch Ophthalmol"},{"key":"2303_CR2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2337\/diacare.25.2.381","volume":"25","author":"M Henricsson","year":"2002","unstructured":"Henricsson M, Berntorp K, Fernlund P, et al. Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care. 2002;25:381\u20135.","journal-title":"Diabetes Care"},{"key":"2303_CR3","first-page":"457","volume":"165","author":"V Poulaki","year":"2004","unstructured":"Poulaki V, Joussen AM, Mitsiades N, et al. Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. AJPA. 2004;165:457\u201369.","journal-title":"AJPA"},{"key":"2303_CR4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","volume":"366","author":"DA Antonetti","year":"2012","unstructured":"Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227\u201339.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2303_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-2005-861362","volume":"37","author":"J Frystyk","year":"2005","unstructured":"Frystyk J. The growth hormone hypothesis - 2005 revision. Horm Metab Res. 2005;37(Suppl 1):44\u20138.","journal-title":"Horm Metab Res"},{"key":"2303_CR6","doi-asserted-by":"crossref","first-page":"E1149","DOI":"10.1152\/ajpendo.00410.2002","volume":"284","author":"J-W Chen","year":"2003","unstructured":"Chen J-W, Ledet T, Orskov H, et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab. 2003;284:E1149\u201355.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2303_CR7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd2359","volume":"6","author":"DR Clemmons","year":"2007","unstructured":"Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007;6:821\u201333.","journal-title":"Nat Rev Drug Discov"},{"key":"2303_CR8","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa1401329","volume":"370","author":"PR Schauer","year":"2014","unstructured":"Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014;370:2002\u201313.","journal-title":"N Engl J Med"},{"key":"2303_CR9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2213-8587(13)70218-3","volume":"2","author":"S Madsbad","year":"2014","unstructured":"Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014;2:152\u201364.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2303_CR10","doi-asserted-by":"crossref","unstructured":"Brynskov T, Laugesen CS, Lykke Svenningsen A, et al. Perioperative monitoring of diabetic retinopathy in patients with type 2 diabetes undergoing gastric bypass surgery: a prospective observational study. Obes Surg. 2016;26:1279\u201386.","DOI":"10.1007\/s11695-015-1936-8"},{"key":"2303_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ghir.2014.09.002","volume":"24","author":"S Savastano","year":"2014","unstructured":"Savastano S, Di Somma C, Barrea L, et al. The complex relationship between obesity and the somatropic axis: the long and winding road. Growth Hormon IGF Res. 2014;24:221\u20136.","journal-title":"Growth Hormon IGF Res"},{"key":"2303_CR12","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1210\/jc.2008-1245","volume":"93","author":"A Kotronen","year":"2008","unstructured":"Kotronen A, Lewitt M, Hall K, et al. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab. 2008;93:4867\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"2303_CR13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2369-14-80","volume":"14","author":"M Reinhard","year":"2013","unstructured":"Reinhard M, Frystyk J, Jespersen B, et al. Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study. BMC Nephrol. 2013;14:80.","journal-title":"BMC Nephrol"},{"key":"2303_CR14","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","volume":"99","author":"M Bidlingmaier","year":"2014","unstructured":"Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99:1712\u201321.","journal-title":"J Clin Endocrinol Metab"},{"key":"2303_CR15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1210\/jc.2013-3060","volume":"99","author":"N Friedrich","year":"2014","unstructured":"Friedrich N, Wolthers OD, Arafat AM, et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99:1675\u201386.","journal-title":"J Clin Endocrinol Metab"},{"key":"2303_CR16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ghir.2015.05.002","volume":"25","author":"The Circulating IGF System in Hepatocellular Carcinoma","year":"2015","unstructured":"The Circulating IGF System in Hepatocellular Carcinoma. The Impact of Liver Status and Treatment. Growth Horm. IGF Res. 2015;25:174\u201381.","journal-title":"Growth Horm. IGF Res"},{"key":"2303_CR17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","volume":"21","author":"JC Levy","year":"1998","unstructured":"Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191\u20132.","journal-title":"Diabetes Care"},{"key":"2303_CR18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0161-6420(86)33606-6","volume":"93","author":"R Klein","year":"1986","unstructured":"Klein R, Klein BE, Magli YL, et al. An alternative method of grading diabetic retinopathy. Ophthalmology. 1986;93:1183\u20137.","journal-title":"Ophthalmology"},{"key":"2303_CR19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/archopht.119.4.547","volume":"119","author":"R Klein","year":"2001","unstructured":"Klein R, Klein BE, Moss SE. How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2001;119:547\u201353.","journal-title":"Arch Ophthalmol"},{"key":"2303_CR20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM198309013090904","volume":"309","author":"TJ Merimee","year":"1983","unstructured":"Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med. 1983;309:527\u201330.","journal-title":"N Engl J Med"},{"key":"2303_CR21","first-page":"2809","volume":"82","author":"JA Janssen","year":"1997","unstructured":"Janssen JA, Jacobs ML, Derkx FH, et al. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:2809\u201315.","journal-title":"J Clin Endocrinol Metab"},{"key":"2303_CR22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1054\/ghir.2000.0140","volume":"10","author":"B Feldmann","year":"2000","unstructured":"Feldmann B, Jehle PM, Mohan S, et al. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins. Growth Hormon IGF Res. 2000;10:53\u20139.","journal-title":"Growth Hormon IGF Res"},{"key":"2303_CR23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2337\/diab.39.2.191","volume":"39","author":"DG Dills","year":"1990","unstructured":"Dills DG, Moss SE, Klein R, et al. Is insulinlike growth factor I associated with diabetic retinopathy? Diabetes. 1990;39:191\u20135.","journal-title":"Diabetes"},{"key":"2303_CR24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2007-1009140","volume":"21","author":"SL Hyer","year":"1989","unstructured":"Hyer SL, Sharp PS, Sleightholm M, et al. Progression of diabetic retinopathy and changes in serum insulin-like growth factor I (IGF I) during continuous subcutaneous insulin infusion (CSII). Horm Metab Res. 1989;21:18\u201322.","journal-title":"Horm Metab Res"},{"key":"2303_CR25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1464-5491.2003.00921.x","volume":"20","author":"J Frystyk","year":"2003","unstructured":"Frystyk J, Bek T, Flyvbjerg A, et al. The relationship between the circulating IGF system and the presence of retinopathy in type 1 diabetic patients. Diabet Med. 2003;20:269\u201376.","journal-title":"Diabet Med"},{"key":"2303_CR26","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1210\/jc.2007-2454","volume":"93","author":"MP Brugts","year":"2008","unstructured":"Brugts MP, Ranke MB, Hofland LJ, et al. Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. J Clin Endocrinol Metab. 2008;93:2539\u201345.","journal-title":"J Clin Endocrinol Metab"},{"key":"2303_CR27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/er.2003-0035","volume":"25","author":"K-C Leung","year":"2004","unstructured":"Leung K-C, Johannsson G, Leong GM, et al. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25:693\u2013721.","journal-title":"Endocr Rev"},{"key":"2303_CR28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-13-0661","volume":"170","author":"PF Vestergaard","year":"2014","unstructured":"Vestergaard PF, Hansen M, Frystyk J, et al. Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. Eur J Endocrinol. 2014;170:229\u201336.","journal-title":"Eur J Endocrinol"},{"key":"2303_CR29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2337\/diacare.23.4.504","volume":"23","author":"MB Grant","year":"2000","unstructured":"Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23:504\u20139.","journal-title":"Diabetes Care"},{"key":"2303_CR30","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1530\/acta.0.1220766","volume":"122","author":"C Kirkegaard","year":"1990","unstructured":"Kirkegaard C, N\u00f8rgaard K, Snorgaard O, et al. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus. Acta Endocrinol. 1990;122:766\u201372.","journal-title":"Acta Endocrinol"},{"key":"2303_CR31","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0161-6420(01)00853-3","volume":"108","author":"Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group","year":"2001","unstructured":"Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology. 2001;108:2266\u201372.","journal-title":"Ophthalmology"},{"key":"2303_CR32","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S0140-6736(02)08655-5","volume":"359","author":"MS Sandhu","year":"2002","unstructured":"Sandhu MS, Heald AH, Gibson JM. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 2002;359:1740\u20135.","journal-title":"Lancet"},{"key":"2303_CR33","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.2337\/db11-1488","volume":"61","author":"SN Rajpathak","year":"2012","unstructured":"Rajpathak SN, He M, Sun Q, et al. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 2012;61:2248\u201354.","journal-title":"Diabetes"},{"key":"2303_CR34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s001250051623","volume":"44","author":"AH Heald","year":"2001","unstructured":"Heald AH, Cruickshank JK, Riste LK, et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001;44:333\u20139.","journal-title":"Diabetologia"},{"key":"2303_CR35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0026-0495(95)90219-8","volume":"44","author":"J Frystyk","year":"1995","unstructured":"Frystyk J, Vestbo E, Skjaerbaek C. Free insulin-like growth factors in human obesity. Metab Clin Exp. 1995;44:37\u201344.","journal-title":"Metab Clin Exp"},{"key":"2303_CR36","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1210\/jc.2009-0614","volume":"94","author":"J Frystyk","year":"2009","unstructured":"Frystyk J, Brick DJ, Gerweck AV, et al. Bioactive insulin-like growth factor-I in obesity. J Clin Endocrinol Metab. 2009;94:3093\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"2303_CR37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/(SICI)1520-7560(199909\/10)15:5<314::AID-DMRR56>3.0.CO;2-E","volume":"15","author":"J Frystyk","year":"1999","unstructured":"Frystyk J, Skjaerbaek C, Vestbo E, et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999;15:314\u201322.","journal-title":"Diabetes Metab Res Rev"},{"key":"2303_CR38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-13-0209","volume":"169","author":"S Pellitero","year":"2013","unstructured":"Pellitero S, Granada ML, Mart\u00ednez E, et al. IGF1 modifications after bariatric surgery in morbidly obese patients: potential implications of nutritional status according to specific surgical technique. Eur J Endocrinol. 2013;169:695\u2013703.","journal-title":"Eur J Endocrinol"},{"key":"2303_CR39","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ijo.0803040","volume":"29","author":"V Giusti","year":"2005","unstructured":"Giusti V, Gasteyger C, Suter M, et al. Gastric banding induces negative bone remodelling in the absence of secondary hyperparathyroidism: potential role of serum C telopeptides for follow-up. Int J Obes Relat Metab Disord. 2005;29:1429\u201335.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2303_CR40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/er.2008-0028","volume":"30","author":"S Jogie-Brahim","year":"2009","unstructured":"Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30:417\u201337.","journal-title":"Endocr Rev"},{"key":"2303_CR41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tem.2009.01.002","volume":"20","author":"SB Wheatcroft","year":"2009","unstructured":"Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and \u22122: implications for metabolic homeostasis. Trends Endocrinol Metab. 2009;20:153\u201362.","journal-title":"Trends Endocrinol Metab"},{"key":"2303_CR42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/01.sla.0000133117.12646.48","volume":"240","author":"F Rubino","year":"2004","unstructured":"Rubino F, Gagner M, Gentileschi P, et al. The early effect of the roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236\u201342.","journal-title":"Ann Surg"},{"key":"2303_CR43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11695-010-0103-5","volume":"20","author":"E Pardina","year":"2010","unstructured":"Pardina E, Ferrer R, Baena-Fustegueras JA, et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg. 2010;20:623\u201332.","journal-title":"Obes Surg"},{"key":"2303_CR44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/eje.1.02069","volume":"154","author":"B Ed\u00e9n Engstr\u00f6m","year":"2006","unstructured":"Ed\u00e9n Engstr\u00f6m B, Burman P, Holdstock C, et al. Effects of gastric bypass on the GH\/IGF-I axis in severe obesity--and a comparison with GH deficiency. Eur J Endocrinol. 2006;154:53\u20139.","journal-title":"Eur J Endocrinol"},{"key":"2303_CR45","doi-asserted-by":"crossref","first-page":"e94613","DOI":"10.1371\/journal.pone.0094613","volume":"9","author":"BK Itariu","year":"2014","unstructured":"Itariu BK, Zeyda M, Prager G, et al. Insulin-like growth factor 1 predicts post-load hypoglycemia following bariatric surgery: a prospective cohort study. PLoS One. 2014;9:e94613\u20139.","journal-title":"PLoS One"},{"key":"2303_CR46","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s11695-009-9843-5","volume":"19","author":"N Vilarrasa","year":"2009","unstructured":"Vilarrasa N, G\u00f3mez JM, Elio I, et al. Evaluation of bone disease in morbidly obese women after gastric bypass and risk factors implicated in bone loss. Obes Surg. 2009;19:860\u20136.","journal-title":"Obes Surg"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-016-2303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11695-016-2303-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-016-2303-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-016-2303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T15:53:13Z","timestamp":1568217193000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11695-016-2303-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,27]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2303"],"URL":"https:\/\/doi.org\/10.1007\/s11695-016-2303-0","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"type":"print","value":"0960-8923"},{"type":"electronic","value":"1708-0428"}],"subject":[],"published":{"date-parts":[[2016,7,27]]}}}